

April 24, 2025 07:38 AM GMT

### 亚洲经济研究 | Asia Pacific

# 观点:从中国转移——对除中 国外的亚洲是不可能的任务

对中国以外的亚洲经济体而言,由于中国是重要的市场、重要的供应国,也是一个重要的对外直接投资来源,因此将业务从中国转移出去以规避美国关税几乎是不可能的。如果这种风险成为现实,这将是对该地区高度贸易导向的增长模式的又一次沉重打击。

### 要点

- 媒体报道称,美国可能正在寻求对除中国以外的亚洲经济体采取措施,限制其对华经济参与。
- 然而,我们认为限制对华贸易几乎是不可能的,因为中国位于该地区跨境生产 网络的中心。
- 中国是终端需求的重要来源、投入品和设备的重要供应国,并提供大量对外直接投资流入,特别是对东盟经济体而言。
- 如果除中国以外的亚洲经济体采取限制性措施,这将导致中国的对等措施,这 意味着该地区的贸易、资本支出和增长前景将受到沉重打击。
- 从本质上讲,这将意味着除中国外的亚洲经济体只是在用一种关税冲击换另一 种关税冲击。

在本报告中,我们分析了哪些经济体可能会被要求对中国实施贸易限制,并解释为什么大多数除中国以外的亚洲经济体会发现实施这些限制非常困难。

This translated report is made available for convenience only and is based on the original research report published in English. In the event of any discrepancy between the translation and the original research report, the content in the original research report will prevail. The original research report can be found here: Asia Economics: The Viewpoint: Shifting Away from China – An Impossible Ask for Asia ex China (22 Apr 2025).

本翻译报告仅供参考之便,基于以英文发表的原版研究报告。如果翻译与原版研究报告有任何不一致之处,以原版研究报告中的内容为准。原版研究报告可在此处查看: Asia Economics: The Viewpoint: Shifting Away from China – An Impossible Ask for Asia ex China (22 Apr 2025)。

MORGAN STANLEY ASIA LIMITED

### Chetan Ahya

亚洲首席经济学家

Chetan.Ahya@morganstanley.com +852 2239-7812

MORGAN STANLEY ASIA (SINGAPORE) PTE.

#### 甘永月

亚洲经济学家

Derrick.Kam@morganstanley.com +65 6834-8272

MORGAN STANLEY ASIA LIMITED

#### 张乐然

经济学家

Jonathan.Cheung@morganstanley.com +852 2848-5652

#### 王奕丹

经济学家

Kelly.Wang@morganstanley.com +852 3963-0891



### 详情

"我确实认为,墨西哥政府提出的一个非常有趣的建议或许是在对华关税方面追随美国…… 我认为若加拿大能有同样的做法,将是一个很好的姿态,因此我们将能形成'北美堡垒',抵挡大量中国进口产品的涌入。"—Scott Bessent,美国财政部长,2025年3月1日。

"归根结底,我们可能会与我们的盟友达成协议……他们是很好的军事盟友,但不是完美的经济盟友。这样我们就能团结起来应对中国。" – Scott Bessent,美国财政部长,2025年4月9日

"中方坚决反对任何一方以牺牲中方利益为代价达成协议",并且"如果出现这种情况,中方绝不接受,并将坚决采取对等反制措施。"-中国商务部发言人,2025年4月20日

**贸易谈判中的买卖价差**: 贸易协议谈判正在进行。据媒体报道,亚洲经济体正主动提出增加采购、降低关税、降低非关税壁垒并增加对美国的投资,有些还承诺加强管控,防止规避关税的行为。然而,也有媒体报道称,作为贸易协议的一部分,美国可能寻求让其他经济体采取措施限制对华贸易。我们之前已经强调过这个问题,考虑到投资者的询问越来越多,我们更深入地研究了这是否会成为除中国以外的亚洲经济体的一个可能选择。我们的结论是,这样做将具有挑战性,而且如果实施,供应链可能面临进一步扰动的风险,并将对该地区的资本支出和贸易周期造成又一次冲击。

哪些经济体可能被要求对中国采取限制性措施——可以说,对美国存在巨大贸易顺差,同时对中国存在巨大贸易逆差的经济体:这样,按净额计算,该经济体可能会被要求采取行动,因为该经济体向美国出售更多商品,同时从中国进口更多商品,或许会被认为拥有对中国的筹码。该地区的三个经济体(越南、泰国和印度)符合这一标准。然而,我们认为这三个经济体将发现很难对中国征收关税(详见下文)。此外,亚洲除中国以外对美国存在最大贸易顺差的四大经济体中有三个(即日本、韩国和台湾)对中国也有贸易顺差。因此,对于这三大贸易伙伴而言,对从中国进口的商品征收关税似乎是不可能的。




Exhibit 1: 越南、泰国和印度对美国存在巨大贸易顺差,对中国存在巨大贸易逆差

资料来源: CEIC、摩根士丹利研究部; 注: 为了保持一致性,使用了美国和中国方面的数据。

**不要低估中国在亚洲地区的作用**:这种方法的支持者可能会辩称,美国消费者是更重要的最终需求来源,因此避免美国关税符合贸易伙伴的利益。然而,他们低估了中国在该地区的作用,原因有以下三个:

- **1)** 除中国以外的亚洲主要出口市场:在除中国内地和香港以外的亚洲地区,对美出口最高,占该地区出口的17.5%。中国以16.6%紧随其后。中国方面的贸易数据显示,除中国以外的亚洲12个经济体中,有7个对中国存在贸易逆差。
- **2) 该地区的重要投资者**:中国占该地区除中国内地对外直接投资流入量的7.9%,与日本、韩国、台湾和印度相比,东盟经济体更依赖于来自中国的对外直接投资流入。
- 3) 关键货品供应商:中国在许多主要出口产品中拥有重要的市场份额,包括投入品、资本货物以及制造技术的供应,特别是在新能源相关领域。这方面的一个关键统计数据是,中国在制造业全球价值链相关产出(定义为一个经济体直接或间接跨越多个边界的制造业产出)中占41%,突显了其在全球价值链中的高参与度。该地区还依赖从中国进口廉价消费品。对中国征收关税将意味着扰乱该地区的跨境生产网络,对除中国以外亚洲地区的经济增长造成严重影响。此外,还将导致消费品价格通胀上升。

正是在这种背景下,我们认为亚洲经济体将不愿对中国设置贸易和投资壁垒,因为这意味着现有商业模式将受到严重破坏。

# 评估实施潜在措施的可能性

美国可以要求亚洲经济体采取三项潜在措施:

- 1) 执行更严格的原产地规则,以限制从中国转运。
- 2) 对中国征收关税。
- 3) 限制来自中国的投资。

我们对每一项措施进行了详细评估,并强调了我们认为除中国以外的亚洲经济体在采取 这些措施时面临的困难和挑战。

# 对中国征收关税——对其他亚洲经济体构成挑战

对中国征收关税是一个困难的任务……: Bessent部长最近的评论(引文见上文)表明,美国可以要求其他亚洲经济体提高对中国的关税,以限制"吸收来自中国的多余商品",甚至可以对来自关系密切的经济体的进口产品征收关税,作为任何贸易协议中的让步。我们一直在强调,鉴于中国在制造业全球价值链中的根深蒂固地位,此类提议将对其他亚洲经济体构成重大挑战(见 The Viewpoint: Seeking Reciprocity – What's Next? 2025年3月17日)。

**…鉴于深厚的区域内贸易和制造业联系…**:例如,**中国占全球制造业价值链相关产出的41%**(定义为一个经济体直接或间接跨越一个以上边界的制造业产出),突显其在全球价值链中的高参与度。亚洲内部的区内贸易也从2017年的3.3万亿美元稳步增长至目前的4.4万亿美元,凸显了亚洲经济体作为一个大型跨境生产网络的事实。

……**还有扰动的风险、更高的通胀以及中国的应对措施**:对从中国进口的产品征收关税可能意味着通胀压力和对国内制造业的干扰。即使对于台湾和澳大利亚等对中国内地存在贸易顺差的经济体,对中国内地征收关税也可能为对等反制打开大门。


Exhibit 2: 亚洲拥有庞大的跨境生产网络,各经济体之间有着深厚的贸易联系



Exhibit 4: 该地区除中国内地和香港以外约17%的出口仍销往中国




**Exhibit 3:** 中国在制造业全球价值链中地位根深蒂固,占全球价值链相关产出的41%



资料来源: WITS、亚洲开发银行、摩根士丹利研究部


Exhibit 5: 越南、台湾、马来西亚、澳大利亚、韩国和泰国对中国内地的商品出口占GDP的百分比更高




资料来源: CEIC、Haver、摩根士丹利研究部

MORGAN STANLEY RESEARCH 5

Exhibit 6: 该地区除中国以外约四分之一的进口来自中国



**Exhibit 7:** 越南、马来西亚、泰国和台湾从中国内地的商品进口占GDP的比例较高




资料来源: CEIC、Haver、摩根士丹利研究部

如果中国以外的亚洲地区对中国征收关税,哪些细分市场将受到最大影响:中国在多种主要产品的全球出口中占据相当大的份额,包括一些主要消费品。例如,中国在手机及其零部件以及电脑及其零部件方面都占据37%的份额。中国在电冰箱、洗衣机和电视等关键白色家电中的市场份额也达到25%至32%。因此,采取措施与中国脱钩并对中国进口产品征收关税将意味着除中国以外亚洲地区的消费品价格上涨。

Exhibit 8: 中国在多个关键产品中拥有相当大的全球出口份额

China top 10 export product by 4 HS digit code: China's share in global export in each product (2023)



资料来源: WITS、摩根士丹利研究部


亚洲经济体最近对中国进口产品采取的关税措施是有针对性的,并且与贸易协定的考虑因素无关:可以肯定的是,该地区的一些经济体,例如韩国以及越南,近几个月来,开始对部分从中国进口的钢材征收反倾销税。然而,我们要指出的是,这主要是对国内生产商提出投诉的回应,并且针对的是特定公司。就越南而言,关税也针对韩国生产商,并且也是暂时性的(持续120天)。

## 限制来自中国的投资——对东盟来说更具挑战性

对于东盟经济体来说,限制来自中国的投资将更具挑战性……: 起点时,中国对东盟经济体的对外投资占其对外直接投资流入总额的11%。可以肯定的是,除新加坡外东盟经济体的实际流量可能被低估。这是因为,来自中国的对外直接投资在到达东盟之前往往会通过新加坡和香港等管道经济体,其中中国内地流入新加坡和香港的对外直接投资占总数的54%。东盟在中国对外直接投资中的边际份额从 2018 年的 15% 上升至 2023 年的20%。在东盟地区,新加坡(+2.6pp)、泰国和越南(+0.6pp)的增幅更为明显。


……但其他亚洲经济体对中国的依赖程度较低:日本、韩国和台湾在起点上对对外直接投资的依赖度较低。如果将印度也包括在内,来自中国的累计对外直接投资流入量占GDP的百分比也很低,并且在中国整体对外直接投资中的份额自2017年以来稳步下降。此外,对于日本、韩国和台湾,流入中国内地的对外直接投资近年来也有所下降,限制了针对对外直接投资的任何潜在反制措施的风险。

Exhibit 9: 对于东盟,来自中国的对外直接投资占对外直接投资流入总额的11%




资料来源:CEIC、摩根士丹利研究部;注:我们使用中国对外直接投资来计算来自中国的对外直接投资流入量,使用个别经济体的国际收支中的对外直接投资流入数据来计算对外直接投资流入总量。

Exhibit 10: 近年来,东盟在中国对外直接投资中所占的份额有所上升...



资料来源: CEIC、摩根士丹利研究部

Exhibit 11: ······而亚洲其他地区的份额 有所下降



资料来源: CEIC、摩根士丹利研究部

Exhibit 12: 此外,日本、韩国和台湾流入中国内地的对外直接投资近年来有所下降……



资料来源: CEIC、摩根士丹利研究部

Exhibit 13: ...限制针对对外直接投资的任何潜在反制措施



资料来源: CEIC、摩根士丹利研究部

### 限制从中国转运

### 我们看到越南、泰国和印度的转运有限,但更多迹象表明国内生产高度依赖中国投

入……:美国政府一再强调希望限制从中国经第三经济体进入美国的转运——转运的定义是从一艘船上卸下货物,然后将这些货物装载到另一艘船上,并前往更远的目的地——因为担心贸易绕道来规避关税。特别是,越南、泰国和印度这三个经济体可能被视为转运中心,因为它们对美国存在巨额贸易顺差,而同时对中国存在巨额贸易逆差。然而,我们在过去的贸易数据中看到,通过这三个经济体转运的迹象有限。相反,我们认为它们对中国的高贸易逆差反映了对中国投入品的高度依赖,这些投入不仅是为了生产向美国出口的商品,也是为了向世界其他地区的出口以及满足国内需求。这种情况反映的并不是贸易绕道,而是巨大的增加值,这种情况越来越多地发生在越南、泰国和印度的国内。

……以越南为例……: 自2017年以来,越南在光学、摄影和精密仪器方面在同一产品类别中对美国的贸易顺差增幅与对中国的贸易逆差增幅基本相当。我们认为,这实际上反映了对中国投入的高度依赖,而不是贸易绕道。事实上,我们之前对产品的逐一分析表明,在越南对美国贸易顺差的增加中,只有35%可以归因于贸易绕道(见 The Viewpoint: Trade Tensions, Supply Chain Diversification, and China,2024年3月19日)。此外,还有一些类别如化学产品和食品和农产品中,越南对中国的贸易逆差增加,而对美国的贸易顺差却没有相应增加,我们认为这反映了制造业为满足内需而生产的商品。最后,在家具、电气机械和设备等产品领域,越南对美国的贸易顺差增幅较大,因此可能被视为存在潜在贸易绕道的领域,但这些产品对中国的贸易逆差增幅,实际上要小得多。因此,这可能意味着越南制造业的本地增加值在增加。

……对于印度而言: 我们还观察了印度的情况,印度在手机和手机投入品方面对中国的贸易逆差增幅远大于其在相同产品方面对美国的贸易顺差增幅。我们认为,对美国出口中来自中国的投入比例过高,可以解释为是为了满足内需以及不仅向美国而且向非美国目的地出口。特别是,来自中国的投入比例高,实际上可能反映了在印度设厂的中国公司的高参与度,以及中国在供应链中占主导地位的产品生产。同样,随着印度近年来协同提高公共资本支出占 GDP 的比例,印度对资本品的内需也反映在印度在机械和运输设备方面对中国的贸易逆差增幅远远大于对美国的贸易顺差增幅。

Exhibit 14: 在亚洲,越南……



资料来源: CEIC、摩根士丹利研究部

Exhibit 15: 泰国



资料来源: CEIC、摩根士丹利研究部

Exhibit 16: ······印度对美国的贸易顺差和对中国的贸易逆差同时增加,但我们看到转运的证据有限



资料来源: CEIC、摩根士丹利研究部

#### Exhibit 17:

在越南,在光学、照相和精密仪器等产品中,对美贸易顺差与对华贸易逆差的增长相匹配,可能反映了对中国投入品的高度依赖

	Food and agricultur al products	Minerals and fuel	Chemicals	classified by	and	Metals, stone and glass	Machinery & mechanica I appliances	machinery & equipmen	transport	Vehicles &	Optical, Photograp hic and Precision Instrumen ts		Other misc. items	Special classificati on provisions
Change in Vietnam's trade balance with US (Feb-25 vs. Dec-17)	0.0	-0.1	0.0	5.5	8.3	3.3	27.9	30.7	-0.2	1.0	1.1	9.0	2	.4 1.7
Change in Vietnam's trade balance with China (Feb-25 vs. Dec-17)	3.6	i -0.5	-3.0	-6.2	-4.8	-8.7	2.5	-11.1	-0.4	-1.8	-1.7	-1.8	-1	6 -8.2

资料来源: CEIC、摩根士丹利研究部

Exhibit 18: 在印度,在电气机械和设备等产品中对华贸易逆差增幅大于在相同产品中对美贸易顺差增幅,表明印度依赖中国投入品以满足内需和/或向非美国目的地出口

	Food and agricultur al products	Minerals	Chemicals	classified by			al	Electrical machiner y & equipmen t	transport	Vehicles & Parts	Optical, Photograp hic and Precision Instrumen ts		Other misc. items	Special classificati on provisions
Change in India trade balance with US (Feb-25 vs. Dec-17)	0.8	-10.2	7.5	1.3	2.9	4.5	3.2	13.6	-0.7	1.1	-0.2	0.5	0.2	0.2
Change in India trade balance with China (Feb-25 vs. Dec-17)	2.4	0.7	-6.9	-4.6	-1.9	-8.3	-12.4	-22.7	-0.3	-1.0	-0.9	0.0	-0.1	0.0

资料来源: CEIC、摩根士丹利研究部



### **Disclosure Section**

Information and opinions in Morgan Stanley Research were prepared or are disseminated by one or more of the following, which accept responsibility for its contents: Morgan Stanley Asia Limited, and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, and/or Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105), Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com which accepts the responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research and their affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

### **Global Research Conflict Management Policy**

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

### **Important Disclosures**

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited (\*MSTL\*). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comision Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan

MORGAN STANLEY RESEARCH 11

Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118)); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the United States by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and the communicated or caused to be communicated. The communicated or caused to be communicated. The communicated or caused to be communicated or caused to be communicated. The communicated or caused to be communicated or caused to be communicated or caused to be communicated. The communicated or caused to be communicated or caused to be communicated or caused to be communicated. The communicated or caused to be communicated or caused to be communicated or caused to be communicated. The communicated or caused to be communicated or caused to be communicated or caused to be communicated. The communicated or caused to be caused to be communicated or caused to be caused to beand A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

### © 2025 Morgan Stanley